Morgan Stanley Remains a Buy on Prestige Estates Projects Limited (PRESTIGE)

Morgan Stanley analyst Praveen Choudhary maintained a Buy rating on Prestige Estates Projects Limited (PRESTIGE – Research Report) on May 30 and set a price target of INR1,700.00. The company's shares closed last Friday at INR1,484.00.
Confident Investing Starts Here:
According to TipRanks, Choudhary is a 3-star analyst with an average return of 1.8% and a 49.15% success rate. Choudhary covers the Consumer Cyclical sector, focusing on stocks such as Melco Resorts & Entertainment, Galaxy Entertainment Group, and Wynn Macau.
Currently, the analyst consensus on Prestige Estates Projects Limited is a Moderate Buy with an average price target of INR1,825.00, implying a 22.98% upside from current levels. In a report released on May 31, Jefferies also maintained a Buy rating on the stock with a INR1,700.00 price target.
Based on Prestige Estates Projects Limited's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of INR20.25 billion and a net profit of INR2.33 billion. In comparison, last year the company earned a revenue of INR16.81 billion and had a net profit of INR2.67 billion

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

Sino Land downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Praveen Choudhary downgraded Sino Land (SNLAY) to Equal Weight from Overweight with a price target of HK$8.60, down from HK$9, as the firm refreshed its ratings and preferences among its Hong Kong property coverage. Hong Kong property prices are down 30% since their peak five years ago and the firm sees several drivers pointing towards a bottoming, says the analyst, who argues investors 'could benefit from a long steady cycle ahead.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue Sign in to access your portfolio

Yahoo

an hour ago

• Yahoo

Musk's xAi increases yield offer on $5 billion debt raise, source says

By Tatiana Bautzer NEW YORK (Reuters) -Elon Musk's xAi is increasing the yield it is offering on a $5 billion debt raise led by Morgan Stanley, a source with knowledge of the matter said on Friday. xAi is offering to pay 12.5% yield on $3 billion in bonds, said the source who asked for anonymity to disclose non-public information. Previously, sources told Reuters the company had offered a 12% yield. xAi is also offering 12.5% fixed yield on a $1 billion term loan and set to price a $1 billion term loan B at 725 basis points over the Secured Overnight Financing Rate, known as SOFR. The term loan B is set to be priced at a discount of 96 cents on the dollar, the source said. The initial offering on the securities was 12% on the fixed loan and 700 basis points over the SOFR on the floating rate loan. Junk-rated bonds paid an average yield to maturity of 7.602%, according to ICE BofA High Yield Index. The deadline for investor commitments was extended from Tuesday to Friday and allocations will be done one day after closing, the source said. If the deal closes on Friday, allocations will happen on Monday. An increase in the yield offer could mean that investors had probably agreed to buy the debt only for a higher yield. The borrower also has lesser flexibility on pricing when investor demand is modest. The xAI offering, which was reported on June 2 as Musk and U.S. President Donald Trump traded barbs over social media, did not receive overwhelming interest from high-yield and leveraged loan investors, Reuters reported earlier this week. Unlike Musk's debt deal when he acquired Twitter, Morgan Stanley did not guarantee how much it would sell or commit its own capital to the deal, in what is called a "best efforts" transaction, according to one person familiar with the terms. xAi did not immediately respond to a request for comment. Morgan Stanley declined to comment.

Yahoo

an hour ago

• Yahoo

BMO says lenacapavir approval for prevention a ‘major win' for Gilead

Although largely as expected by investors, BMO Capital says lenacapavir's approval for prevention, now known as Yeztugo, marks 'a major win for Gilead (GILD)' in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue Cautious Optimism for Gilead Sciences Amid Yeztugo's Market Challenges Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead Mizuho says Gilead Yeztugo label looks clean Gilead Sciences' Yeztugo Approval and Market Expansion Drive Buy Rating Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option